The Stroke Prevention by Aggressive Reduction in Cholesterol Levels ( SPARCL ) trial assessed the effect of statin treatment on the risk of nonfatal and fatal stroke in subjects with a noncardioembolic stroke or transient ischemic attack , no known coronary heart disease , and low-density lipoprotein cholesterol between @ and @ mmol/L ( @-@ mg/dL ) .